Paradigm Therapeutics Named Prix Galien Finalist for Second Year
Image
Mount Pleasant, S.C. – October 13, 2026 -- Paradigm Therapeutics, Inc. has been named a finalist for the 2026 Prix Galien USA "Best Start-Up" Award, its second consecutive nomination after being a nominee in 2025.
The clinical-stage biopharmaceutical company is developing SD-101 (ZorblesiaTM), a topical cream for wounds and lesions across the entire skin surface in patients with Epidermolysis Bullosa (EB). The Galien Foundation manages the awards, which will be presented on October 29, 2026, at the American Museum of Natural History in New York City.